Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs HSBC Holdings plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while HSBC Holdings plc trades at $104.06 (market cap $353.82B). The key difference: HSBC Holdings plc is far larger — about 12× Alnylam Pharmaceuticals, Inc.'s market cap, and HSBC Holdings plc pays a 3.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HSBC | |
|---|---|---|
Market Cap | $29.60B | $353.82B |
Sector | Health | Technology |
52-Week High | $491.22 | $107.86 |
52-Week Low | $205.48 | $63.84 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
HSBC trades at $104.05, up 0.71% today, with a bullish technical signal from moving averages and a P/E of 14.74. The bank reported strong Q2 2026 results, including a 7% revenue increase and a $1 billion buyback, while maintaining a 34.54% net income margin. Recent news highlights leadership changes and China-related market pressures.
Outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory shifts and valuation concerns after a 40% run. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid growth and external headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
